Similar articles

• Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study.

  Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, Wong M, Padanilam X, Dziwiecki A, van Helden PD, Siwendu S, Jarand J, Menezes CN, Burns A, Victor T, Warren R, Grobusch MP, van der Walt M, Kvasnovsky C. Dheda K, et al. Lancet. 2010 May 22;375(9728):1798-807. doi: 10.1016/S0140-6736(10)60492-8. Lancet. 2010. PMID: 20488525
• Antiretroviral therapy for control of the HIV-associated MDR and XDR tuberculosis epidemic in South Africa.

  Lawn SD, Wood R. Lawn SD, et al. Am J Respir Crit Care Med. 2010 Dec 15;182(12):1567; author reply 1568-9. doi: 10.1164/ajrccm.182.12.1567. Am J Respir Crit Care Med. 2010. PMID: 21159908 No abstract available.
• Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa.

  Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G; Tugela Ferry Care and Research (TF CARES) Collaboration. Andrews JR, et al. J Infect Dis. 2007 Dec 1;196 Suppl 3:S482-90. doi: 10.1086/521121. J Infect Dis. 2007. PMID: 18181698 Review.
• The emerging crisis of drug-resistant tuberculosis in South Africa: lessons from New York City.

  Murphy RA. Murphy RA. Clin Infect Dis. 2008 Jun 1;46(11):1729-32. doi: 10.1086/587903. Clin Infect Dis. 2008. PMID: 18426372
• Extensively drug-resistant tuberculosis: new strains, new challenges.

  Banerjee R, Schecter GF, Flood J, Porco TC. Banerjee R, et al. Expert Rev Anti Infect Ther. 2008 Oct;6(5):713-24. doi: 10.1586/14787210.6.5.713. Expert Rev Anti Infect Ther. 2008. PMID: 18847407 Review.